The story
2008 – Mesynthes Limited (Wellington, New Zealand) was founded by Brian Ward.
2008 – First patent of ovine forestomach matrix and reinforced biologics.
2009 – Endoform Natural™ cleared by the US FDA for treatment of acute and chronic wounds.
2010 – OFM first described in the scientific literature.
2010 – OFM reinforced biologics first described in scientific literature.
2011 – Partnership with Hollister Wound Care (Libertyville, IL) to launch and commercialize Endoform Natural™.
2012 – Partnership with Tela Bio Inc. to commercialize reinforced biologics.
2013 – OFM reinforced biologics (Ovitex®) cleared by US FDA for hernia repair.
Read the full text
2014 – Corporate headquarters relocated from Wellington New Zealand to Auckland New Zealand.
2015 – Company rebrands to Aroa Biosurgery Limited.
2016 – Ovitex® launched in USA in partnership with Tela Bio Inc (Malvern, PA).
2017 – Endoform Antimicrobial™ cleared by the US FDA.
2017 – Myriad Matrix™ cleared by the US FDA.
2018 – Endoform Antimicrobial™ launched in USA.
2018 – Aroa Biosurgery establishes a joint venture with Hydrofera LLC (Manchester, CT) to sell products for wound care and plastics and reconstructive surgery.
2018 – Aroa Biosurgery opens first US office (San Diego, California).
2019 – Myriad Matrix™ launched in USA for plastic and reconstructive surgery.
2020 – Symphony™ cleared by US FDA.
2020 – Aroa Biosurgery lists on the Australian Securities Exchange.
2021 – Joint venture with Hydrofera LLC dissolved and Aroa's direct sales expanded.
2021 – Myriad Morcells™ cleared by US FDA.
2021 – Myriad Morcells™ launched in USA for plastic and reconstructive surgery.
2022 – First scientific publication describing novel dead-space management negative pressure system.
2023 – Symphony™ launched in USA for advanced wound care.
From Wikipedia’s article on Aroa Biosurgery, shared under CC BY-SA 4.0.4